By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:


SEARCH JOBS

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.

YEAR FOUNDED:

February 8, 2008

LEADERSHIP:

Founder: Martin Shkreli

CEO: Stephen Aselage

CFO: Laura Clague

JOBS:

Please click here for Retrophin job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products


Key Statistics


Email: info@retrophin.com
Ownership: Public

Web Site: Retrophin
Employees:
Symbol: RTRX
 



Industry
Biotechnology






Company News
Retrophin (RTRX) To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series 9/15/2016 8:58:21 AM
Ligand (LGND) Partner Retrophin (RTRX) Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis 9/7/2016 10:57:38 AM
Retrophin (RTRX) Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis 9/7/2016 10:02:05 AM
Martin Shkreli's Former Firm Retrophin (RTRX) Considering Acquisition of Bay Area's Raptor (RPTP), Deal Could be Worth $589 Million+ 8/18/2016 5:29:43 AM
Retrophin (RTRX) Appoints Neil Mcfarlane Chief Operating Officer 8/15/2016 12:13:50 PM
Retrophin (RTRX) To Report Second Quarter 2016 Financial Results 7/22/2016 7:56:26 AM
Retrophin (RTRX) Appoints Roy D. Baynes, M.D., Ph.D., To Board Of Directors 7/20/2016 10:30:49 AM
Retrophin (RTRX) Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson’s Disease And Movement Disorders 6/23/2016 7:59:56 AM
Retrophin (RTRX) Pays Up to $24 Million for Rights to PBC Candidate from Asklepion 6/21/2016 6:39:27 AM
Retrophin (RTRX) To Present At The Barclays Global Healthcare Conference 3/4/2016 8:04:18 AM
12345678910
//-->